基于既往辅助生殖周期取卵数的累积活产率预测
丹麦全国队列研究纳入2002至2011年间启动辅助生殖(ART)治疗、使用自体卵母细胞的30486名女性,随访至4个完整新鲜ART周期(含后续冻融胚胎移植周期)。首个完整周期未活产者,首周期取卵数越多,第二、三周期活产几率越高;作者认为可结合既往失败次数与卵巢反应为夫妇提供年龄分层的预后咨询。
要点
- 首周期取卵0-3枚相比,取卵4-9枚、10-15枚、>15枚者第二、三周期活产几率依次升高。
- 首、二周期取卵总数>6枚者,第三完整周期活产比值比明显升高。
- 因卵巢过度刺激综合征(OHSS)住院的比例首周期为1.7%,第二、三周期分别为1.3%和1.0%。
核心结论
- 首周期取卵数与后续周期的累积活产率(CLBR)相关,既往治疗反应可预测未来周期结局。
- 作者认为可据此为再次接受生育治疗的夫妇提供年龄分层的活产机会与OHSS风险预后咨询,反映既往失败尝试与卵巢反应。
研究设计与样本
- 丹麦全国队列研究,数据来自丹麦国家体外受精登记库(1994年起覆盖公立与私立诊所),并与医学出生登记库交叉链接以识别治疗相关出生与自然受孕出生。
- 纳入2002至2011年间启动ART治疗、使用自体卵母细胞的全部女性,N=30486,随访至4个完整新鲜ART周期(含后续冻融胚胎移植周期)或首次活产或2011年12月。
- CLBR按启动ART治疗的全部女性中活产者比例计算,包括中途退出者(随访期内无活产或未继续治疗)。
- 对末次治疗后随访满1年的女性,采用多因素logistic回归分析取卵数对CLBR的影响,校正女性年龄与不孕原因。
- 报告因OHSS住院的情况。
主要发现
- 1、2、3个完整ART周期后归因于ART治疗的CLBR分别为26.4%[95%CI 25.9-26.9]、42.6%[42.0-43.1]和51.3%[50.7-51.9]。
- 1、2、3个完整周期后归因于非ART受孕(自然受孕或宫腔内人工授精)的CLBR分别为5.3%[5.0-5.6]、8.3%[8.0-8.7]和10.6%[10.3-11.0]。
- 首完整周期未活产者中,与首周期取卵0-3枚相比,首周期取卵4-9枚者第二、三周期活产比值比为1.18[1.07-1.30],10-15枚者为1.41[1.27-1.57],>15枚者为1.63[1.42-1.88]。
- 首、二周期均未活产者中,首、二新鲜周期取卵总数>6枚者第三完整周期活产比值比明显升高(相比取卵总数0-6枚者)。
- 因OHSS住院的比例首周期为1.7%,第二、三周期分别降至1.3%和1.0%。
关键数值与推荐
- CLBR计算以启动ART治疗的全部女性为分母,包括中途退出者。
- 多因素logistic回归校正女性年龄与不孕原因。
- 取卵数分组:0-3枚、4-9枚、10-15枚、>15枚;首、二周期取卵总数分组:0-6枚与>6枚。
临床怎么用
- 作者认为可据此为再次接受生育治疗的夫妇提供年龄分层的活产机会与OHSS风险预后咨询,反映既往失败尝试与卵巢反应。
局限性
- 尽管登记为强制,仍可能有治疗周期未登记于体外受精登记库。
- 取卵数信息缺失最可能为随机信息丢失。
- 取卵数>15枚的女性观察例数少,这些出生率应谨慎解读。
- 未获得促排卵所用促性腺激素剂量的信息,也未获得后续周期剂量调整的信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is the number of aspirated oocytes in the first ART cycle associated with the cumulative live birthrates (CLBR) in subsequent cycles? SUMMARY ANSWER: The number of aspirated oocytes in the first cycle was associated with CLBR in subsequent cycles. Previous treatment response predicts outcome in future cycles. WHAT IS KNOWN ALREADY: Previous reports have shown a positive association between the number of retrieved oocytes and live birthrate per fresh treatment cycle. This has also been shown for the CLBR in one complete ART-cycle, including possible subsequent frozen-thawed transfers (FER). It has been shown that women with less than five oocytes in the first cycle have poorer outcome within six complete cycles than women with more than 12 oocytes, suggesting that the number of aspirated oocytes in the first cycle may be reproduced in later cycles. However, other studies have shown that an initial low treatment response may be improved with increased gonadotrophin start-dose. STUDY DESIGN, SIZE, DURATION: The Danish National IVF-registry includes all ART treatments in public and private clinics since 1994. Treatment-cycles were cross-linked with the Medical Birth Registry, identifying treatment-related births and natural conception births. This national cohort study includes all women starting ART treatments with homologous eggs between 2002 and 2011, N = 30 486. Subjects were followed for up to four fresh ART-cycles including subsequent FER-cycles (=four complete cycles), until the first livebirth, or until December 2011. PARTICIPANTS/MATERIALS, SETTING, METHODS: The CLBR within 1-4 complete ART-cycles were calculated as the proportion of women with a livebirth, out of all women initiating ART-treatment, including drop-outs (no livebirth or no continued treatment within follow-up). In women with one year follow-up from last treatment, multivariate logistic regression analysis assessed impact of retrieved oocytes on CLBR, adjusting results for female age and cause of infertility. Hospital admission due to ovarian hyperstimulation syndrome (OHSS) was reported. MAIN RESULTS AND THE ROLE OF CHANCE: After one, two and three complete ART-cycles, the CLBRs attributable to ART treatment were 26.4% [95%CI 25.9-26.9], 42.6% [42.0-43.1] and 51.3% [50.7-51.9], respectively. The CLBR attributable to non-ART related conception (natural conception or intrauterine insemination) were 5.3% [5.0-5.6], 8.3% [8.0-8.7] and 10.6% [10.3-11.0], after one, two and three complete cycles. In women without a live birth in the first complete cycle, the number of aspirated oocytes predicted the outcome in the second and third cycle: When compared to women with 0-3 aspirated oocytes in the first cycle, the odds for live birth in the second and third cycle was 1.18 [1.07-1.30] for women with 4-9 aspirated oocytes in the first cycle, 1.41 [1.27-1.57] for women with 10-15 aspirated oocytes and 1.63 [1.42-1.88] for women with more than 15 aspirated oocytes. For women without a livebirth in the first and second cycle, the sum of aspirated oocytes predicted outcome in the third complete cycle. Women with a sum larger than six aspirated oocytes, had marked increased odds ratios for livebirth in the third complete cycle, compared to women with a sum of 0-6 oocytes in the first and second fresh cycle. Incidence of hospital-admission due to OHSS was 1.7% in the first cycle, decreasing to 1.3% and 1.0% in the second and third cycles. LIMITATIONS, REASONS FOR CAUTION: Although mandatory, there may be treatment-cycles not registered in the IVF-registry. Missing information in number of aspirated oocytes are most likely random losses of information. There were few observations in women with more than 15 aspirated oocytes and these birthrates should be interpreted cautiously. Information on gonadotrophin dose used for stimulation was not available, nor was information on dose adjustments in subsequent cycles. WIDER IMPLICATIONS OF THE FINDINGS: With these results we can counsel couples returning for fertility treatments, providing an age-stratified revised prognosis for chances of live birth and risk of OHSS, reflecting prior failed attempts and previous ovarian response. STUDY FUNDING/COMPETING INTEREST(S): This study was unconditionally funded by Ferring Pharmaceuticals and ReproUnion. The funders had no role in the study design, data collection and interpretation, or decision to submit the work for publication. The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: The study was approved by the Danish Data Protection Agency (J.nr. 2012-41-1330).
引用
- Malchau SS, Henningsen AA, Forman J, et al. Cumulative live birth rate prognosis based on the number of aspirated oocytes in previous ART cycles. Hum Reprod. 2019. PMID: 30541039. doi:10.1093/humrep/dey341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。